A study utilizing the DNA methyltransferase (DNMT) inhibitor decitabine to treat PC3 prostate cancer cells resulted in the demethylation of the DKK3 promoter, leading to elevated DKK3 expression and the inhibition of TGF-β/Smad-dependent transcriptional activity. This evidence concerns the gene DNMT1 and prostate cancer.